UK Capital Investment Response to Recommendation
TOTAL SCORE: 8
Score
A1 (Feasibility increased by continuance of pandemic): 0
A2 (Necessity increased by covid pandemic): 0
A3 (political viability): 0
B1 (Relevance to the specific goal of increasing HALE by 5 years by 2035): +1
B2 (Relevance to general goal of biomedical healthy life extension): +1
C1 (Market readiness applicability): -1
C2 (Project readiness): 0
C3 (Move to market readiness): 0
D1 (Actionability): 0
D2 (Degree of measurability): +1
D3 (Degree of leveraging cross-sector inputs): +1
D4 (Awareness of international context): +1
D5 (Resourcefulness): +1
D6 (Reorganisation): +1
E (Disruptiveness): +2
F (Dividends - does the recommendation aid in social activity and inclusivity?): 0
This recommendation scores strongly on (D4), assuming the UK government does not overlook lessons from abroad, such as the biomedical research incentives provided by countries such as Australia described in Aging Analytics Agency’s response to the Committee’s recommendations.
RECOMMENDATION SUMMARY
“The UK has historically been a major player in drug research and development, and has the potential to be a key player in the development of treatments targeting the processes of ageing. However, companies in the UK struggle to commercialise such innovations and often have to move abroad to access finance. (Paragraph 191)
We recommend that the Government ensure the UK remains a global leader in drug research and development. It should work towards making the UK a more attractive environment for growth capital investment, to stop UK innovations moving abroad after the discovery stage of research. (Paragraph 192)”
Score
A1 (Feasibility increased by continuance of pandemic): 0
A2 (Necessity increased by covid pandemic): 0
A3 (political viability): 0
B1 (Relevance to the specific goal of increasing HALE by 5 years by 2035): +1
B2 (Relevance to general goal of biomedical healthy life extension): +1
C1 (Market readiness applicability): -1
C2 (Project readiness): 0
C3 (Move to market readiness): 0
D1 (Actionability): 0
D2 (Degree of measurability): +1
D3 (Degree of leveraging cross-sector inputs): +1
D4 (Awareness of international context): +1
D5 (Resourcefulness): +1
D6 (Reorganisation): +1
E (Disruptiveness): +2
F (Dividends - does the recommendation aid in social activity and inclusivity?): 0
This recommendation scores strongly on (D4), assuming the UK government does not overlook lessons from abroad, such as the biomedical research incentives provided by countries such as Australia described in Aging Analytics Agency’s response to the Committee’s recommendations.
RECOMMENDATION SUMMARY
“The UK has historically been a major player in drug research and development, and has the potential to be a key player in the development of treatments targeting the processes of ageing. However, companies in the UK struggle to commercialise such innovations and often have to move abroad to access finance. (Paragraph 191)
We recommend that the Government ensure the UK remains a global leader in drug research and development. It should work towards making the UK a more attractive environment for growth capital investment, to stop UK innovations moving abroad after the discovery stage of research. (Paragraph 192)”